Supplementary Figure S5 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy | Synapse
October 17, 2025
Supplementary Figure S5 from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy
Key Points
Blinatumomab shows steady state concentrations in both adult and pediatric patients receiving chemotherapy.
Concentration levels vary by patient weight and age, highlighting individual differences in drug metabolism.
Data include subgroups of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Observational analysis across patient demographics demonstrates the importance of tailored therapy in leukemia treatment.
Abstract
Figure S5 shows the steady state concentrations of blinatumomab in adult and pediatric patients with R/R BCP ALL by weight (a) and age(b) subgroups.